ABSTRACT
The effcacy of Remaxol was studied in the treatment of patients with acute biliary pancreatitis under clinical and laboratory con- ditions by the recommended indices, as well as by the markers of endogenous intoxication, the intensity of lipid peroxidation, activity of some enzymes and indicators of hypoxia. The use of Remaxol in the treatment of acute biliary pancreatitis was highly resultant in correction (prevention of progression) of the functional hepatic failure and homeostatic disorders as a whole. It was demonstrated that the hepatoprotective effect of the drug was based on its ability to reduce oxidative stress, to inhibit excessive phospholipase activity and to alleviate the signs of general hypoxia.
Subject(s)
Liver Failure/prevention & control , Pancreatitis/drug therapy , Succinates/administration & dosage , Acute Disease , Adult , Aged , Female , Humans , Liver Failure/etiology , Liver Failure/pathology , Male , Middle Aged , Pancreatitis/complications , Pancreatitis/pathologyABSTRACT
This clinico-laboratory study showed that antihypoxant remaxol promoted normalization of lipid metabolism in acute peritonitis and significantly reduced membrane-destabilizing events. This resulted in rapid elimination of the inflammatory process in the abdominal cavity and lowering of the intensity of endogenous intoxication. This beneficial effect decreased the severity of myocardial lesions and resulted in the normalization of erythrocyte function. It is concluded that the regulatory action of remaxol on lipid metabolism is due to its ability to control free radicals in lipid peroxidation and reduce phospholipase A2 activity.
